New Agents To Invade UC Market As Biosimilars Put Pressure On Stalwarts
Executive Summary
The ulcerative colitis pipeline is bustling with novel drugs, with new modes of action, that are ready to take on the market leading biologic therapies and their biosimilar counterparts; five launches are anticipated from four different drug classes before 2022.
You may also be interested in...
UC Market Gets Increasingly Crowded – But High Unmet Need Remains
Market Snapshot: The ulcerative colitis market looks set to experience strong pricing pressure over the next three to five years, with leading players losing exclusivity for their drugs and a flood of novel entrants set to hit the market.
Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis
FDA approved the JAK inhibitor as the first oral medicine for moderate to severe ulcerative colitis, providing Pfizer with fertile new commercial ground for the blockbuster drug.
Deals Shaping Medtech And Diagnostics, September 2021
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.